Evidence map›Paper›PMID 39939491›Full record

ReviewReviews in endocrine & metabolic disorders2025

Rathke's cleft cyst: From history to molecular genetics.

Aysa Hacioglu, Halil Tekiner, Meric A Altinoz, Gazanfer Ekinci, Jean-François Bonneville, Kaan Yaltirik, Aydin Sav, Ugur Ture, Fahrettin Kelestimur

Abstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Indications and Limits of Endoscopic Endonasal Approaches in Pediatric Neurosurgery.Advances and technical standards in neurosurgery · 2026
    Review
  5. A Data-Driven Approach for Rathke's Cleft Cysts Management.Diagnostics (Basel, Switzerland) · 2025
    Article
  6. The endocrine spectrum of Rathke cleft cysts.Frontiers in endocrinology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aysa HaciogluDepartment of Endocrinology, Erciyes University, Kayseri, Turkey.
Halil TekinerDepartment of Medical History, Erciyes University, Kayseri, Turkey.
Meric A AltinozDepartment of Biochemistry, Acibadem University, Istanbul, Turkey.
Gazanfer EkinciDepartment of Radiology, Yeditepe University, Istanbul, Turkey.
Jean-François BonnevilleDepartments of Medical Imaging and Endocrinology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
Kaan YaltirikDepartment of Neurosurgery, Yeditepe University, Istanbul, Turkey.
Aydin SavDepartment of Pathology, Yeditepe University, Istanbul, Turkey.
Ugur TureDepartment of Neurosurgery, Yeditepe University, Istanbul, Turkey.
Fahrettin KelestimurDepartment of Endocrinology, Yeditepe University School of Medicine, Istanbul, Turkey. fahrettin.kelestemur@yeditepe.edu.tr.ORCID http://orcid.org/0000-0002-2861-4683

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A Rathke's cleft cyst (RCC) is a remnant of the embryologic Rathke's pouch and a common pituitary lesion. A true RCC is lined with ciliated cuboidal or columnar epithelia with occasional goblet cells and squamous metaplasia. A RCC is frequently diagnosed incidentally through magnetic resonance imaging and computed tomography of the brain or pituitary gland. Presentation can range from an asymptomatic clinical picture to a rapidly progressive disease. RCC are located most often in the sellar and suprasellar regions and a careful differential diagnosis is crucial, especially to exclude craniophryngioma. Recent studies illuminate novel molecular mechanisms and markers for understanding the pathogenesis of RCC. PROP-1, a paired-like homeodomain transcription factor, controls pituitary ontogeny and its high expression induces RCCs. Both transgenic mouse models and immunohistochemical analysis of human RCCs indicate that the leukemia inhibitory factor is involved in pathogenesis. The expression of cytokeratins 8 and 2 in RCCs, but not in craniopharyngiomas, and the presence of beta-catenin mutations in many craniopharyngiomas, but not in RCCs, help with the differential diagnosis. For asymptomatic and small RCCs, observation is appropriate, with serial magnetic resonance imaging and hormonal investigation depending on the patient's clinical status. Surgical resection may be required for symptomatic RCC and recurrence rates are generally low. For patients with a recurrence, stereotactic radiosurgery is an effective approach with low risk.

Indexed as

Central Nervous System CystsPituitary NeoplasmsAnimalsHumansMolecular BiologyCleftCystHypopituitarismLuschkaPituitaryRathke

Identifiers

PMID39939491
PMCPMC11920404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.